Received Jun 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
received Shingrix in April 2022 and did not complete the series; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose in APR 2022, batch no 3527M, expiry date 03-JUN-2023). On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: received Shingrix in April 2022 and did not complete the series). The outcome of the incomplete course of vaccination was not applicable. Additional Information: GSK Receipt Date: 11-JUN-2025 The pharmacist reported that the patient received 1st dose of Shingrix and asked do we need now to restart the series or can she get the second dose 3 years later. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.